Skip to main content
. Author manuscript; available in PMC: 2006 Jan 25.
Published in final edited form as: J Urol. 2005 Aug;174(2):741–746. doi: 10.1097/01.ju.0000164730.38431.5c

Figure 2. combination treatment of KU19-19 at a constant ratio of 1:10 (NV1066: mitomycin-C).

Figure 2

Figure 2

Figure 2

KU19-19 cell line treated with a combination of NV1066 in three different multiplicities of infection (MOI 0.05, 0.1, 0.5) and three dosages of mitomycin-C (MMC- 0.5,1,5 μGr/ml) at a constant dose ratio of 1:10. Y axis demonstrates the cell kill as calculated by 1% of control cell survival. The synergistic effect of the combined treatment (COMB) at day 5 after treatment is most notable in the lower doses of treatment.